Enhancers of endocannabinoid signaling are potential analgesics, but they cause unacceptable psychiatric side effects. A new study reports an inhibitor of endocannabinoid breakdown that has analgesic activity and cannot enter the CNS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Calignano, A., La Rana, G., Giuffrida, A. & Piomelli, D. Nature 394, 277–281 (1998).
Walker, J.M. & Hohmann, A.G. Handb. Exp. Pharmacol. 168, 509–554 (2005).
Agarwal, N. et al. Nat. Neurosci. 10, 870–879 (2007).
Clapper, J.R. et al. Nat. Neurosci. 13, 1265–1270 (2010).
Marrs, W.R. et al. Nat. Neurosci. 13, 951–957 (2010).
Kinsey, S.G. et al. J. Pharmacol. Exp. Ther. 330, 902–910 (2009).
Kunos, G., Osei-Hyiaman, D., Bátkai, S., Sharkey, K.A. & Makriyannis, A. Trends Pharmacol. Sci. 30, 1–7 (2009).
Di Marzo, V. et al. Nature 410, 822–825 (2001).
Engeli, S. et al. Diabetes 54, 2838–2843 (2005).
Christensen, R., Kristensen, P.K., Bartels, E.M., Bliddal, H. & Astrup, A. Lancet 370, 1706–1713 (2007).
Tam, J. et al. J. Clin. Invest. 120, 2953–2966 (2010).
Groblewski, T. et al. Int. Cannabinoid Res. Soc. Abstr. 38 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Lovinger, D. Endocannabinoids rein in pain outside the brain. Nat Neurosci 13, 1155–1156 (2010). https://doi.org/10.1038/nn1010-1155
Published:
Issue Date:
DOI: https://doi.org/10.1038/nn1010-1155
